Zevra therapeutics receives fda acceptance of resubmission of nda for arimoclomol as a treatment for niemann-pick disease type c

Arimoclomol nda has been assigned a pdufa action date of june 21, 2024 celebration, fla., jan. 08, 2024 (globe newswire) -- zevra therapeutics, inc.  (nasdaqgs: zvra) (zevra or the company), a rare disease therapeutics company, today announced that the u.s. food and drug administration (fda) has acknowledged receipt of the resubmission of the new drug application (nda) for arimoclomol as an orally-delivered, first-in-class treatment for niemann-pick disease type c.
ZVRA Ratings Summary
ZVRA Quant Ranking